Related Experiment Videos
Cardiac allograft vasculopathy
1Nursing Service, Department of Veteran Affairs, Edward Hines, Jr. Hospital Hines, Illinois.
Insights
Cardiac allograft vasculopathy (CAV) is a serious complication after heart transplants, affecting graft survival. This review covers CAV
Area of Science:
- Cardiology
- Transplantation Immunology
Background:
- Improving survival rates in cardiac transplant patients highlight long-term complications.
- Cardiac allograft vasculopathy (CAV) is a significant cause of graft loss.
- CAV is a form of coronary artery disease unique to transplant recipients.
Purpose of the Study:
- To explore the pathophysiology, risk factors, detection, and treatment of CAV.
- To increase awareness of CAV as a critical post-transplant complication.
- To provide a comprehensive overview for clinicians managing cardiac transplant recipients.
Main Methods:
- Review of existing literature on cardiac allograft vasculopathy.
- Analysis of immune-related responses and other contributing factors.
- Discussion of current and emerging diagnostic techniques.
Main Results:
- CAV develops early post-transplant, often undetected initially.
- Estimated incidence of 12% per year in cardiac transplant recipients.
- Primarily an immune response, but hyperlipidemia and obesity are risk factors.
Conclusions:
- CAV is a major impediment to long-term cardiac allograft survival.
- Early detection and management are crucial.
- Understanding risk factors aids in prevention and treatment strategies.
Abstract:
As the survival rates for cardiac transplant patients improve, the long-term complications of the procedure are becoming apparent. One such complication is a rapidly progressing form of coronary artery disease known as cardiac allograft vasculopathy (CAV). CAV is a major limiting factor in long-term graft survival. It is thought to develop immediately after transplantation, although initially it may be unrecognized because of a lack of sensitive screening techniques. It is estimated that 12% of cardiac transplant recipients will develop CAV each year after transplantation. Most researchers agree that CAV is primarily an immune-related response to transplantation. However, other factors such as hyperlipidemia and obesity have also been implicated as predictors of CAV. This article explores the pathophysiology, risk factors, detection, and treatment of CAV in the cardiac transplant population.